کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8795164 | 1602987 | 2018 | 19 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
چشم پزشکی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The introduction of antivascular endothelial growth factor agents such as ranibizumab and aflibercept has revolutionized the management of neovascular age-related macular degeneration. A number of randomized clinical trials have shown that ranibizumab and aflibercept produce similar efficacy and safety outcomes. Most of the switching studies published to date show that efficacy benefits are uncontrolled, retrospective trials with limitations in terms of their selection, monitoring, numbers, and assessment criteria. Based on the published literature to date, we propose arguments for and against switching antivascular endothelial growth factor agents, provide our own perspective on this topic, and suggest a focus for future research.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Survey of Ophthalmology - Volume 63, Issue 5, SeptemberâOctober 2018, Pages 638-645
Journal: Survey of Ophthalmology - Volume 63, Issue 5, SeptemberâOctober 2018, Pages 638-645
نویسندگان
Irmela MD, Mark C. MB BS, PhD, Eric H. MD, PhD,